Last reviewed · How we verify
PCV21 vaccine
PCV21 vaccine stimulates the body's immune system to produce antibodies against 13 serotypes of pneumococcal bacteria.
PCV21 vaccine stimulates the body's immune system to produce antibodies against 13 serotypes of pneumococcal bacteria. Used for Prevention of invasive pneumococcal disease caused by 13 serotypes of Streptococcus pneumoniae.
At a glance
| Generic name | PCV21 vaccine |
|---|---|
| Also known as | 515 |
| Sponsor | Sanofi |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This vaccine works by introducing inactivated fragments of the pneumococcal bacteria to the body, which triggers an immune response and the production of antibodies. These antibodies help to neutralize and eliminate the bacteria, thereby preventing infections.
Approved indications
- Prevention of invasive pneumococcal disease caused by 13 serotypes of Streptococcus pneumoniae
Common side effects
- Pain, redness, swelling, or itching at the injection site
- Fatigue
- Headache
Key clinical trials
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |